ecrin-mdr-crcClinical2022IPD Sharing (as of October 2023): No Description: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://bit.ly/IPD21Colorectal CancerColorectal NeoplasmsColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2742179United StatesJapanSpain8ECRIN MDRRecruitingfalseAnti-CEACAM5 ADC M9140 in Advanced Solid TumorsThe purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary clinical activity of M9140 in advanced solid tumors. Study details include: * Study Duration per participant: Approximately 4 months * M9140 is not available through an expanded access program2022-08-152742179NCT054640302022-500508-23JPRN-jRCT2031220313